STOCK TITAN

Philip Morris International Presents at 2024 Deutsche Bank Global Consumer Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Philip Morris International (NYSE: PM) announced at the 2024 Deutsche Bank Global Consumer Conference that it is raising its 2024 full-year reported and adjusted diluted EPS forecast due to favorable currency factors. The revised forecast for reported diluted EPS is $5.77 to $5.89, with adjusted diluted EPS expected to be $6.26 to $6.38, representing a 4.2% to 6.2% increase compared to 2023. Excluding currency impacts, this translates to a growth forecast of 9.0% to 11.0%. The positive outlook is supported by strong momentum in their IQOS and ZYN products and the resilience of their combustible business.

Positive
  • Raised 2024 full-year reported diluted EPS forecast to $5.77-$5.89.
  • Adjusted diluted EPS forecast increased to $6.26-$6.38, reflecting a 4.2%-6.2% increase from 2023.
  • Excluding currency impacts, the EPS growth forecast is 9.0%-11.0%.
  • Strong performance driven by IQOS and ZYN products.
  • Resilient combustible business contributing to positive forecast.
Negative
  • Growth forecast adjustment primarily due to favorable currency impact, not underlying business improvement.
  • Adverse currency impact of $0.29 per share in the forecast.

Insights

Philip Morris International's (PMI) decision to raise its 2024 full-year reported and adjusted diluted EPS forecast for currency impacts projects a positive financial outlook. The revision underscores PMI's confidence in its financial health, driven by strong product performance, notably IQOS and ZYN. However, the underlying growth assumptions remain steady, which could indicate a stable yet cautious outlook amidst fluctuating exchange rates.

EPS (Earnings Per Share) is a critical metric for investors, as it signifies a company's profitability per share of stock. PMI's revised EPS forecast of $5.77 to $5.89 reflects a solid base even with currency adjustments. The adjusted diluted EPS range of $6.26 to $6.38 implies a growth of 4.2% to 6.2% compared to $6.01 in 2023, which in a currency-neutral scenario stands at 9.0% to 11.0%.

For retail investors, these figures suggest PMI's robust operational performance and strategic product positioning. The maintained currency-neutral growth forecast points to a resilient business model that can weather currency volatility. This is particularly relevant given the global nature of PMI's business and the ongoing currency market fluctuations.

PMI's raise in their EPS forecast for 2024, driven primarily by product momentum from IQOS and ZYN, highlights pivotal market dynamics. IQOS, a heated tobacco product and ZYN, a nicotine pouch product, cater to evolving consumer preferences towards smokeless alternatives. The increasing adoption of these products indicates a shift in market demand, potentially reducing PMI's dependence on traditional combustible tobacco.

This transition aligns with broader industry trends where companies are diversifying portfolios to include reduced-risk products. For investors, understanding this shift is important as it impacts long-term revenue streams and market positioning. While the traditional tobacco market faces regulatory and health challenges, products like IQOS and ZYN offer growth routes.

By focusing on these innovative products, PMI demonstrates a proactive approach to staying relevant in a changing landscape. However, the long-term success of these products will depend on regulatory acceptance and consumer adoption rates across different markets.

Raises, for Currency Only, 2024 Full-Year Reported and Adjusted Diluted EPS Forecast, While Reaffirming Currency-Neutral Adjusted Diluted EPS Growth Forecast of 9.0% to 11.0%

STAMFORD, CT--(BUSINESS WIRE)-- Regulatory News:

Philip Morris International Inc.’s (PMI) (NYSE: PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2024 Deutsche Bank Global Consumer Conference.

The event will be webcast live in listen-only mode, beginning at approximately 8:30 a.m. CEST (2:30 a.m. ET), at www.pmi.com/2024deutschebank and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). Presentation slides will also be available on the same site and the App. An archived copy of the webcast will be available until Friday, July 5, 2024.

"After an excellent first-quarter performance, we continue to expect strong first-half results," said Emmanuel Babeau, Chief Financial Officer. “Today, we are raising - for currency only - our 2024 full-year EPS forecast, which is underpinned by the strong momentum of IQOS and ZYN, and the resilience of the combustible business.”

2024 Full-Year Forecast

PMI revises its 2024 full-year reported diluted EPS forecast - for currency only - to a range of $5.77 to $5.89, at prevailing exchange rates. Excluding a total 2024 adjustment of $0.49 per share, the forecast range for adjusted diluted EPS of $6.26 to $6.38 represents a projected increase of 4.2% to 6.2% versus $6.01 in 2023. Excluding an adverse currency impact, at prevailing exchange rates, of $0.29 per share, this continues to represent growth of 9.0% to 11.0%, as shown below.

The assumptions underlying this forecast remain unchanged versus those communicated by PMI in its earnings release of April 23, 2024.

Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections.

 

Full-Year

 

2024
Forecast

 

2023

 

Growth

 

 

 

 

 

 

 

 

 

 

Reported Diluted EPS

$5.77

-

$5.89

 

$ 5.02

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

 

 

Asset impairment and exit costs(1)

0.09

 

0.06

 

 

 

 

Termination of distribution arrangement in the Middle East

 

0.04

 

 

 

 

Impairment of goodwill and other intangibles

0.01

 

0.44

 

 

 

 

Amortization of intangibles(2)

0.43

 

0.25

 

 

 

 

Charges related to the war in Ukraine

 

0.03

 

 

 

 

Swedish Match AB acquisition accounting related items

 

0.01

 

 

 

 

Income tax impact associated with Swedish Match AB financing

0.07

 

(0.11)

 

 

 

 

South Korea indirect tax charge

 

0.11

 

 

 

 

Termination of agreement with Foundation for a Smoke-Free World

 

0.07

 

 

 

 

Fair value adjustment for equity security investments

(0.08)

 

(0.02)

 

 

 

 

Tax items

(0.03)

 

0.11

 

 

 

 

Total Adjustments

0.49

 

0.99

 

 

 

 

Adjusted Diluted EPS

$6.26

-

$6.38

 

$ 6.01

 

4.2%

-

6.2%

Less: Currency

(0.29)

 

 

 

 

 

 

Adjusted Diluted EPS, excluding currency

$6.55

-

$6.67

 

$ 6.01

 

9.0%

-

11.0%

(1) See impairment and exit costs section in Q1’24 Earnings Release for details

(2) See forecast assumptions section in Q1’24 Earnings Release for details

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested over $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products. As of December 31, 2023, PMI's smoke-free products were available for sale in 84 markets, and PMI estimates that approximately 33 million adults around the world use PMI's smoke-free products. Smoke-free business accounted for approximately 37% of PMI’s total full-year 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.

Forward-Looking and Cautionary Statements

This press release contains projections of future results and goals and other forward-looking statements, including statements regarding expected financial or operational performance; capital allocation plans; investment strategies; regulatory outcomes; market expectations; and business plans and strategies. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco and/or nicotine use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of natural disasters and pandemics on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our smoke-free products performance.

PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2023, and the Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.

Investor Relations:

Stamford, CT: +1 (203) 904 2410

Lausanne: +41 582 424 666

Email: InvestorRelations@pmi.com

Media: David Fraser

Lausanne: +41 582 424 500

Email: David.Fraser@pmi.com

Source: Philip Morris International

FAQ

What is Philip Morris International's 2024 EPS forecast?

Philip Morris International has raised its 2024 full-year reported diluted EPS forecast to $5.77-$5.89, and adjusted diluted EPS to $6.26-$6.38.

What is the expected growth rate for Philip Morris's adjusted diluted EPS in 2024?

The adjusted diluted EPS is expected to grow by 4.2% to 6.2% compared to 2023, or 9.0% to 11.0% excluding currency impacts.

What drove Philip Morris's positive EPS forecast for 2024?

The forecast is driven by the strong performance of IQOS and ZYN products and the resilience of the combustible business.

What was the impact of currency on Philip Morris's 2024 EPS forecast?

The revised forecast includes an adverse currency impact of $0.29 per share.

Philip Morris International Inc.

NYSE:PM

PM Rankings

PM Latest News

PM Stock Data

189.41B
1.55B
0.12%
80.52%
0.54%
Tobacco
Cigarettes
Link
United States of America
STAMFORD